CA3232799A1 - Methods of treating multiple myeloma - Google Patents

Methods of treating multiple myeloma Download PDF

Info

Publication number
CA3232799A1
CA3232799A1 CA3232799A CA3232799A CA3232799A1 CA 3232799 A1 CA3232799 A1 CA 3232799A1 CA 3232799 A CA3232799 A CA 3232799A CA 3232799 A CA3232799 A CA 3232799A CA 3232799 A1 CA3232799 A1 CA 3232799A1
Authority
CA
Canada
Prior art keywords
day
antigen
antibody
subject
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232799A
Other languages
English (en)
French (fr)
Inventor
Phoenix HO
Heather Alane VAN EPPS
Mary Campbell
Amy Kim
Shinta CHENG
Todd Shearer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
SpringWorks Therapeutics Inc
Original Assignee
Seagen Inc
SpringWorks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc, SpringWorks Therapeutics Inc filed Critical Seagen Inc
Publication of CA3232799A1 publication Critical patent/CA3232799A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3232799A 2021-09-23 2022-09-20 Methods of treating multiple myeloma Pending CA3232799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163247637P 2021-09-23 2021-09-23
US63/247,637 2021-09-23
PCT/US2022/076694 WO2023049694A1 (en) 2021-09-23 2022-09-20 Methods of treating multiple myeloma

Publications (1)

Publication Number Publication Date
CA3232799A1 true CA3232799A1 (en) 2023-03-30

Family

ID=83996580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3232799A Pending CA3232799A1 (en) 2021-09-23 2022-09-20 Methods of treating multiple myeloma

Country Status (6)

Country Link
US (1) US20240343819A1 (https=)
EP (1) EP4405393A1 (https=)
JP (1) JP2024534602A (https=)
CA (1) CA3232799A1 (https=)
TW (1) TW202327650A (https=)
WO (1) WO2023049694A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
WO2025117764A1 (en) * 2023-12-01 2025-06-05 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
BR112021020409A2 (pt) * 2019-04-10 2021-12-07 Glaxosmithkline Ip Dev Ltd Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase

Also Published As

Publication number Publication date
JP2024534602A (ja) 2024-09-20
TW202327650A (zh) 2023-07-16
WO2023049694A1 (en) 2023-03-30
US20240343819A1 (en) 2024-10-17
EP4405393A1 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
US20240343819A1 (en) Methods of treating multiple myeloma
JP7086066B2 (ja) Ｐｄ－１に対する抗体及びその使用
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
DK2703486T3 (en) ANTI-B7-H3 ANTIBODY
JP2024012313A (ja) 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
US20250387476A1 (en) Methods of Treating Cancer
US20230118517A1 (en) Methods of treating multiple myeloma
JP2020515247A (ja) 抗ｏｘ４０抗体およびその使用
JP2023544407A (ja) 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
JP7350756B2 (ja) 抗ヒトｐｄ－ｌ２抗体
EP3746479A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
US20220306743A1 (en) Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
US20250249115A1 (en) Combination therapy for treating tumor antigen expressing cancers
KR20230121759A (ko) 항-marco 항체 및 이의 용도
US20220340662A1 (en) Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
HK40085355A (en) Methods of treating multiple myeloma
EP4329806A1 (en) Anti-siglec compositions and uses thereof
KR20260013511A (ko) 암 치료를 위한 조합 요법

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240808

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808